Chen Xiao, E Yan, Wang Wei, Huang Yong, Xin Xueting, Chen Gang
Department of Neurology, Haimen People's Hospital, Nantong, Jiangsu, 226100, People's Republic of China.
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210000, People's Republic of China.
Int J Gen Med. 2025 Jun 25;18:3393-3400. doi: 10.2147/IJGM.S529326. eCollection 2025.
Emerging experimental evidence has established that high-mobility group box 1 (HMGB-1) plays a pivotal role in cerebral ischemia pathogenesis, primarily through mediating neuroinflammatory cascades following ischemic injury. This study sought to investigate the potential association between circulating HMGB-1 levels and the risk of malignant brain edema (MBE) in patients undergoing mechanical thrombectomy (MT).
This study prospectively recruited patients presenting with large vessel occlusive stroke in the anterior circulation and receiving MT treatment. Serum HMGB-1 levels were quantitatively assessed for all participants upon hospital admission. MBE was defined as defined as a midline shift of ≥5 mm observed on follow-up neuroimaging after MT. Multivariate logistic regression analyses were conducted to investigate the potential correlation between serum HMGB-1 concentrations and MBE development.
Among the cohort of 261 eligible patients (mean age: 69.7 years; male: 166 [63.6%]), 59 individuals (22.6%; 95% confidence interval [CI]: 17.6%-28.3%) developed MBE. After adjusted for demographic characteristics and other potential confounders, multivariate logistic regression demonstrated that higher serum HMGB-1 levels were associated with an increased risk of MBE (odds ratios [OR], highest vs lowest quartile: 3.130; 95% CI, 1.077-9.098; = 0.036). In addition, restricted cubic spline analysis revealed a dose-response relationship between elevated serum HMGB-1 levels and MBE risk ( for non-linearity=0.764).
This study confirmed that elevated circulating HMGB-1 levels were significantly associated with MBE after MT. These findings suggested that HMGB-1 could serve as a predictive biomarker for post-MT MBE risk, potentially enabling early identification of high-risk patients who may benefit from intensified monitoring or targeted therapeutic interventions.
新出现的实验证据表明,高迁移率族蛋白B1(HMGB-1)在脑缺血发病机制中起关键作用,主要是通过介导缺血性损伤后的神经炎症级联反应。本研究旨在探讨接受机械取栓术(MT)的患者循环中HMGB-1水平与恶性脑水肿(MBE)风险之间的潜在关联。
本研究前瞻性招募了前循环大血管闭塞性卒中且接受MT治疗的患者。所有参与者入院时均对血清HMGB-1水平进行定量评估。MBE定义为MT术后随访神经影像学检查发现中线移位≥5mm。进行多因素逻辑回归分析以研究血清HMGB-1浓度与MBE发生之间的潜在相关性。
在261例符合条件的患者队列中(平均年龄:69.7岁;男性:166例[63.6%]),59例(22.6%;95%置信区间[CI]:17.6%-28.3%)发生了MBE。在对人口统计学特征和其他潜在混杂因素进行校正后,多因素逻辑回归表明,较高的血清HMGB-1水平与MBE风险增加相关(比值比[OR],最高四分位数与最低四分位数:3.130;95%CI,1.077-9.098;P=0.036)。此外,限制性立方样条分析显示血清HMGB-1水平升高与MBE风险之间存在剂量反应关系(非线性检验P=0.764)。
本研究证实MT术后循环中HMGB-1水平升高与MBE显著相关。这些发现表明,HMGB-1可作为MT术后MBE风险的预测生物标志物,有可能早期识别可能从强化监测或靶向治疗干预中获益的高危患者。